Among other items: Corus Pharma and its chief executive, Bruce Montgomery, have filed papers in King County Superior Court formally denying a complaint that it unlawfully obtained valuable intellectual property; and United and Delta airlines yesterday matched an airfare increase that American Airlines launched.
The Economic Development Council of Seattle and King County has dropped its lanky, functional name for a snazzier moniker and logo.
The 33-year-old group said it will be known as “enterpriseSeattle,” a name it says reflects the region’s global and digital competitiveness and connects the “Seattle” brand to surrounding cities such as Kent, Renton and Auburn, which are part of the development council, but lack national or international profile.
A new Space Needle logo with swirls and digitized squares suggests movement of ideas and technology.
Corus Pharma papers deny Chiron accusation
Most Read Stories
- Woman, 71, lost in Olympics with dog, built shelter, ate ants
- Foreign buyers drop off as Seattle housing market hits hottest tempo since 2006 bubble
- 3 teens killed in Lynnwood crash from Mill Creek high school
- What drivers can and cannot do under Washington state's new distracted-driving law
- Are Seattle housing prices headed for a crash? | Jon Talton
Corus Pharma and its chief executive, Bruce Montgomery, have filed papers in King County Superior Court formally denying a complaint that it unlawfully obtained valuable intellectual property.
Chiron, a large biotech company based in Emeryville, Calif., sued the Seattle company and Montgomery last month over development of an inhalable drug to treat cystic fibrosis.
ZymoGenetics details bleeding-disorder treatment
ZymoGenetics gave an investor update in New York yesterday, outlining its progress in developing treatments for bleeding disorders, autoimmune diseases and cancer.
The company said it has completed a study of Thrombin, its treatment for surgical bleeding, among 42 patients undergoing spinal surgery. ZymoGenetics said it met its main goal of showing safety, and also reached a goal of stopping bleeding on time. The company said it plans to craft a pivotal trial in the second half of next year based on the results, once they are combined with more preliminary results.
ZymoGenetics also said it plans to complete preliminary human trials of its TACI-Ig drug for lupus and rheumatoid arthritis in 2005. It said it plans to begin testing the treatment in several cancers this quarter.
Nation / World
United, Delta match American’s fare rise
United and Delta airlines yesterday matched an airfare increase that American Airlines launched, but it wasn’t clear whether other competitors would follow.
American raised many of its domestic round-trip fares by $10 in its latest attempt to offset the high cost of fuel.
The increase excludes routes where the Fort Worth-based carrier competes with discount airlines, including Southwest Airlines and JetBlue Airways.
It also does not affect flights from Miami, Fort Lauderdale and West Palm Beach, Fla., where the airline recently implemented a low-fare structure on all of its flights.
“Once again this is in response to the rising cost of fuel,” said spokeswoman Jacquie Young. “That’s been a major issue for us all year.”
Typically, fare increases are rescinded if one or more of the major airlines does not match the increase.
Compiled from Seattle Times business staff and The Associated Press